分子指导治疗用于系统治疗耐药的晚期原发性肝癌:2025法国基因组医学计划结果
2025法国基因组医学计划纳入120例系统治疗进展的晚期原发性肝癌患者,采用全基因组、全外显子及RNA测序识别可靶向变异。103例可解读基因组中67例(HCC 59%、CCA 80%、cHCC-CCA 78%)存在可操作变异;31例接受匹配治疗,10例(32.3%)达疾病控制,且仅见于ESCAT I-III变异者,中位PFS在达疾病控制者显著延长(11.8 vs 2.4个月,p=0.009)。
要点
- 系统治疗耐药的晚期肝癌中,综合基因组测序可行,近三分之二可解读病例存在可操作变异。
- 匹配治疗疾病控制率32.3%,仅ESCAT I-III变异者获益,ESCAT IV无临床获益。
- 达疾病控制者中位PFS显著优于进展者(11.8 vs 2.4个月,p=0.009)。
核心结论
- 对系统治疗耐药的晚期原发性肝癌行综合基因组分析可行,ESCAT I/II/III变异匹配治疗可使部分经治患者达疾病控制。
研究设计与样本
- 2025法国基因组医学计划纳入8中心120例系统治疗进展的原发性肝癌患者,行全基因组、全外显子及RNA测序,结果经分子肿瘤委员会审核。
主要发现
- 120例中HCC 80例、CCA 25例、cHCC-CCA 9例、纤维板层癌4例、肝肉瘤1例、HEHE 1例。
- HCC常见变异为TP53(46%)、TERT(44%)、CTNNB1(20%);CCA为TP53(55%)、ARID1A(20%)、BAP1;cHCC-CCA为TP53(67%)、PIK3CA(22%)、ARID2(11%)。
- 103例可解读基因组中67例有至少一个可操作变异(HCC 59%、CCA 80%、cHCC-CCA 78%)。
- 31例接受匹配治疗(1例ESCAT I、2例II、21例III、7例IV),69%既往接受≥2线系统治疗。
- 10/31例(32.3%)达疾病控制(HCC 23%、CCA 75%、cHCC-CCA 67%),仅见于ESCAT I-III变异者(41.7%),ESCAT IV无临床获益。
临床怎么用
- 对系统治疗耐药的晚期原发性肝癌,可考虑早期行全基因组、全外显子及RNA测序以匹配ESCAT I-III变异治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Advanced primary liver cancers remain difficult to treat after failure of first-line therapy. The 2025 French Genomic Medicine Initiative aimed to identify actionable targets for personalized treatment. METHODS: Patients with PLC progressing on systemic therapy were enrolled across eight centers. Tumor and blood samples were analyzed using whole-genome, whole-exome, and RNA sequencing to identify targetable alterations classified according to the ESCAT scale. Genomic results and potential therapies were reviewed by a molecular tumor board. RESULTS: A total of 120 patients were enrolled: 80 with hepatocellular carcinoma (HCC), 25 with cholangiocarcinoma (CCA), 9 with combined hepatocellular-cholagiocarcinoma (cHCC-CCA), 4 with fibrolamellar carcinoma, 1 with hepatic sarcoma, and 1 with hepatic epithelioid hemangioendothelioma (HEHE). Recurrent genomic alterations included TP53 (46%), TERT (44%), and CTNNB1 (20%) in HCC; TP53 (55%), ARID1A (20%), and BAP1 in CCA; and TP53 (67%), PIK3CA (22%), and ARID2 (11%) in cHCC-CCA. Among 103 interpretable genomes, 67 patients harbored at least one actionable alteration (HCC: 59%, CCA: 80%, cHCC-CCA: 78%). Thirty-one patients (22 HCC, 5 CCA, 3 cHCC-CCA, 1 HEHE, 1 hepatic sarcoma) received matched therapies: 1 ESCAT I, 2 ESCAT II, 21 ESCAT III, and 7 ESCAT IV. These patients had received prior systemic therapy, including ≥2 lines in 69% of cases. Disease control (DC; radiological response/stable disease) was achieved in 10 of 31 patients (32.3%), including 23% of HCC, 75% of CCA, and 67% of cHCC-CCA cases. DC was observed exclusively in patients treated for ESCAT I-III alterations (41.7%), with no clinical benefit in those treated for ESCAT IV alterations. Median progression-free survival was significantly longer in patients achieving DC compared with those with progressive disease (11.8 vs. 2.4 months; p = 0.009). CONCLUSIONS: Comprehensive genomic profiling in advanced PLC refractory to systemic treatment is feasible and associated with DC in a subset of pretreated patients with ESCAT I/II/III alterations. IMPACT AND IMPLICATIONS: Our research demonstrates that comprehensive genomic profiling through the French Genomic Medicine 2025 (FGM2025) initiative is feasible and clinically impactful in advanced primary liver cancers, including rare subtypes. By integrating whole-genome, whole-exome, and RNA sequencing, actionable genomic alterations were identified in nearly two-thirds of patients - well beyond the reach of standard next-generation sequencing panels. These findings provide a strong rationale for implementing early, broad molecular profiling to optimize therapeutic matching, preserve liver function, and expand access to precision medicine. Ultimately, our work highlights the transformative potential of genomics-guided strategies in improving clinical outcomes and advancing personalized care for patients with hepatobiliary malignancies.
引用
- Campani C, Laurent-Puig P, Villeret F, et al. Molecularly guided therapies for advanced primary liver cancers refractory to systemic treatment: Results from the 2025 French genomic medicine initiative. J Hepatol. 2026. PMID: 41865801. doi:10.1016/j.jhep.2026.03.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。